Transmembrane-Bound IL-15–Promoted Epithelial-Mesenchymal Transition in Renal Cancer Cells Requires the Src-Dependent Akt/GSK-3β/β-Catenin Pathway

[1]  S. Batra,et al.  Guggulsterone decreases proliferation and metastatic behavior of pancreatic cancer cells by modulating JAK/STAT and Src/FAK signaling. , 2013, Cancer letters.

[2]  H. Kantarjian,et al.  Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies. , 2013, Leukemia research.

[3]  A. Ravaud,et al.  Combination therapy in metastatic renal cell cancer. , 2013, Seminars in Oncology.

[4]  D. P. Mishra,et al.  Pharmacological modulation of beta-catenin and its applications in cancer therapy , 2013, Journal of cellular and molecular medicine.

[5]  G. Camussi,et al.  Interleukin-15 is a major regulator of the cell-microenvironment interactions in human renal homeostasis. , 2013, Cytokine & growth factor reviews.

[6]  E. Maher.  Genomics and epigenomics of renal cell carcinoma. , 2013, Seminars in cancer biology.

[7]  H. Axelson,et al.  Renal stem cells and their implications for kidney cancer. , 2013, Seminars in cancer biology.

[8]  C. Morrison,et al.  Pharmacologic Blockade of FAK Autophosphorylation Decreases Human Glioblastoma Tumor Growth and Synergizes with Temozolomide , 2012, Molecular Cancer Therapeutics.

[9]  F. Rodriguez,et al.  E-cadherin's dark side: possible role in tumor progression. , 2012, Biochimica et biophysica acta.

[10]  S. Chouaib,et al.  Interleukin-15 Plays a Central Role in Human Kidney Physiology and Cancer through the γc Signaling Pathway , 2012, PloS one.

[11]  D. Sharma,et al.  Leptin-induced Epithelial-Mesenchymal Transition in Breast Cancer Cells Requires β-Catenin Activation via Akt/GSK3- and MTA1/Wnt1 Protein-dependent Pathways* , 2012, The Journal of Biological Chemistry.

[12]  G. Camussi,et al.  Differentiation therapy: targeting human renal cancer stem cells with interleukin 15. , 2011, Journal of the National Cancer Institute.

[13]  M. F. Shannon,et al.  An autocrine TGF-β/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition , 2011, Molecular biology of the cell.

[14]  T. Waldmann,et al.  Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. , 2011, Blood.

[15]  R. Silverman,et al.  Reverse signaling through membrane-bound interleukin-15. , 2011, The Journal of Biological Chemistry.

[16]  A. Taherian,et al.  Differences in integrin expression and signaling within human breast cancer cells , 2011, BMC Cancer.

[17]  Merlin C. Thomas,et al.  The molecular mediators of type 2 epithelial to mesenchymal transition (EMT) and their role in renal pathophysiology , 2010, Expert Reviews in Molecular Medicine.

[18]  A. Douvdevani,et al.  Association between renal injury and reduced interleukin-15 and interleukin-15 receptor levels in acute kidney injury. , 2010, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[19]  M. Oya,et al.  Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma , 2009, British Journal of Cancer.

[20]  C. Meyer,et al.  Extracellular matrix modulates sensitivity of hepatocytes to fibroblastoid dedifferentiation and transforming growth factor β–induced apoptosis , 2009, Hepatology.

[21]  Laurence Zitvogel,et al.  Dendritic Cell-Derived Exosomes Promote Natural Killer Cell Activation and Proliferation: A Role for NKG2D Ligands and IL-15Rα , 2009, PloS one.

[22]  S. Chouaib,et al.  Human renal cancer cells express a novel membrane-bound interleukin-15 that induces, in response to the soluble interleukin-15 receptor alpha chain, epithelial-to-mesenchymal transition. , 2009, Cancer research.

[23]  Simone Brabletz,et al.  E-cadherin, β-catenin, and ZEB1 in malignant progression of cancer , 2009, Cancer and Metastasis Reviews.

[24]  E. Tartour,et al.  The soluble alpha chain of interleukin-15 receptor: a proinflammatory molecule associated with tumor progression in head and neck cancer. , 2008, Cancer research.

[25]  R. Paus,et al.  IL-15/IL-15 receptor biology: a guided tour through an expanding universe. , 2006, Cytokine & growth factor reviews.

[26]  T. Waldmann.  The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design , 2006, Nature Reviews Immunology.

[27]  R. Paus,et al.  The interleukin‐15/interleukin‐15 receptor system as a model for juxtacrine and reverse signaling , 2006, BioEssays : news and reviews in molecular, cellular and developmental biology.

[28]  S. Chouaib,et al.  Membrane-bound and soluble IL-15/IL-15Ralpha complexes display differential signaling and functions on human hematopoietic progenitors. , 2005, Blood.

[29]  A. Plet,et al.  Natural, Proteolytic Release of a Soluble Form of Human IL-15 Receptor α-Chain That Behaves as a Specific, High Affinity IL-15 Antagonist1 , 2004, The Journal of Immunology.

[30]  P. Colarusso,et al.  Monocyte Surface-Bound IL-15 Can Function as an Activating Receptor and Participate in Reverse Signaling1 , 2004, The Journal of Immunology.

[31]  T. Waldmann,et al.  IL-15Rα Recycles and Presents IL-15 In trans to Neighboring Cells , 2002 .

[32]  D. Salant,et al.  IL-15, a survival factor for kidney epithelial cells, counteracts apoptosis and inflammation during nephritis. , 2002, The Journal of clinical investigation.

[33]  B. Seliger,et al.  Constitutive and IFN-gamma regulated expression of IL-7 and IL-15 in human renal cell cancer. , 1999, International journal of oncology.

[34]  T. Dassopoulos,et al.  IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. , 1998, Immunity.

[35]  T. Strom,et al.  Intragraft IL-15 transcripts are increased in human renal allograft rejection. , 1996, Transplantation.

[36]  N. Copeland,et al.  Functional Characterization of the Human Interleukin-15 Receptor αChain and Close Linkage of IL15RA and IL2RA Genes (*) , 1995, The Journal of Biological Chemistry.

[37]  D. Cosman,et al.  Utilization of the beta and gamma chains of the IL‐2 receptor by the novel cytokine IL‐15. , 1994, The EMBO journal.